Answers are grounded in this paper and cite their sources.
Demonstrates the anticancer potential of Ru(II) complexes in ovarian cancer, suggesting a new treatment pathway.
Electronic fine-tuning of Ru( ii ) complexes drives redox behavior and anticancer activity, with RuNH2 emerging as a highly selective, submicromolar candidate that outperforms cisplatin and stands out as a promising agent for ovarian cancer therapy.
No takes yet. Share an insight, caveat, or question.
Dutra et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: